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Genetic variation among 166 isolates of human adenovirus 7 (Ad7) obtained from 1966 to 2000 from the
United States and Eastern Ontario, Canada, was determined by genome restriction analysis. Most (65%)
isolates were identified as Ad7b. Two genome types previously undocumented in North America were also
identified: Ad7d2 (28%), which first appeared in 1993 and was later identified throughout the Midwest and
Northeast of the United States and in Canada; and Ad7h (2%), which was identified only in the U.S. South-
west in 1998 and 2000. Since 1996, Ad7d2 has been responsible for several civilian outbreaks of Ad7 dis-
ease and was the primary cause of a large outbreak of respiratory illness at a military recruit training
center. The appearance of Ad7d2 and Ad7h in North America represents recent introduction of these
viruses from previously geographically restricted areas and may herald a shift in predominant genome
type circulating in the United States.
uman adenoviruses (Ads) comprise 51 serotypes (1);
they are ubiquitous and responsible for a wide range of
clinical syndromes. Among recognized serotypes, Ad type 7
(Ad7) (and to a lesser extent Ad type 3) is most often associ-
ated with severe disease (2). Although Ad7 infections typi-
cally result in mild upper respiratory tract illnesses and
conjunctivitis, infections can also lead to more serious lower
respiratory tract illnesses, disseminated disease, and death,
particularly in infants and persons with underlying immuno-
logic or respiratory compromise (3-7). Ad7 infections have
also been associated with diseases of the central nervous sys-
tem (8,9) and long-term respiratory sequelae that include bron-
chiectasis and hyperlucent lung or McLeod syndrome (10).
Ad7 accounts for nearly 20% of all Ads reported to the
World Health Organization (11), and family clusters and insti-
tutional and communitywide outbreaks of Ad7 disease have
been extensively documented (5,12-18). Three types of out-
breaks have been described (12): i) outbreaks that occur during
the winter months among institutionalized infants (<2 years of
age) that result in high rates of severe illness and death; ii)
periodic nonseasonal communitywide outbreaks involving
older children and adults with infrequent serious outcomes;
and iii) outbreaks of acute respiratory disease among new mil-
itary recruits. Outbreaks of acute respiratory disease due pri-
marily to Ad7 and Ad4 were an important cause of illness in
new military recruits in the United States until live enteric-
coated Ad4 and Ad7 vaccines began to be routinely adminis-
tered in 1971 (19). The recent cessation of production and
administration of these vaccines has resulted in a resumption
of Ad-associated acute respiratory disease outbreaks at mili-
tary recruit training centers throughout the United States (20-
22).
To facilitate study of the molecular epidemiology of Ad7, a
classification system based on restriction enzyme analysis of
Ad genomic DNA was devised by Li and Wadell (23) and later
revised by Li et al. (24). Their system uses BamHI as the
“type” defining enzyme, with different genome types denoted
with a character, e.g., “p” for the Ad7 prototype strain,
Gomen; and then “a” through “k.” Genome types that are fur-
ther distinguished by restriction pattern with additional
selected enzymes are given an Arabic numeral (e.g., Ad7p, p1,
a, a1-6). Their system has been widely used to correlate
genome types with geographic distribution and pathogenic
potential.
Both globally dispersed and geographically restricted
genome types of Ad7 have been identified by restriction analy-
sis, and regional shifts or replacements of predominant
genome types have been documented on different continents.
Among the 3 Ad7 genome types first distinguished by restric-
tion analysis (25), two shown to be serologically distinct (26)
were designated Ad7p (Gomen) and Ad7a (S-1058), and a
third, designated Ad7b, was thought to be associated with
more severe illness (12). Ad7b eventually spread worldwide
(27-30), displacing formerly common genome types (i.e.,
Ad7p, Ad7a, Ad7a1-6, Ad7c, and others) that are now rarely
detected. Exceptions to this pattern have been reported. In the
former Soviet Union, a successive shift from Ad7a and
Ad7a1-5 to Ad7f1 during 1976-1979 and 1986-1988 was
reported (31). In South America, a shift from Ad7c to Ad7h
occurred in 1986 (32), and Ad7h has subsequently caused seri-
ous respiratory illness in infants and young children in Chile
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and Argentina (33,34). In the early 1980s in China, a new
genome type, Ad7d (27), replaced Ad7b as the predominant
circulating virus. Recent reports suggest that Ad7d and Ad7h
have spread beyond their formerly geographically restricted
regions. Ad7d was identified in Japan in 1987 (35), and coun-
trywide epidemics of Ad7 that began in 1995 in Korea (18;
Hoan-Jong Lee, pers. comm.) and Japan (15, 36) were attrib-
uted to Ad7d and a closely related genomic variant, Ad7d2,
respectively. Ad7d2 has emerged as the predominant strain cir-
culating in Israel since 1992 (37). Ad7h was first reported out-
side South America in 1996, in Japan (36,38).
Beginning in the fall of 1998, an outbreak of Ad7 infection
occurred at a pediatric chronic-care facility in Chicago and
subsequently spread to a tertiary-care hospital, where staff
from two clinic units were infected (17). This multi-site out-
break was associated with considerable illness and death
among residents of the chronic-care facility. Isolates from this
outbreak were identified by restriction enzyme analysis as
Ad7d2. The appearance of this new genome type prompted us
to study the temporal and geographic distribution of Ad7
genome types in the United States to better characterize the
emergence and spread of this virus.
Materials and Methods
Ads
Of 297 Ad field isolates obtained from the Centers for Dis-
ease Control and Prevention (CDC) archives, state public
health laboratories, university hospitals, and military training
centers, 166 confirmed as Ad7 were selected for genome type
analysis (Table 1). Of these, 116 were obtained from 1966 to
2000 from civilians in 25 states and eastern Ontario, Canada;
50 were obtained from February 1997 to May 1998 from mili-
tary recruits attending training centers in five states (20). Iso-
lates were selected to achieve broad geographic and temporal
distribution. Because detailed demographic, epidemiologic,
and clinical data from patients were limited, they were not
included in this report. Most civilian isolates were obtained
from individual cases or family clusters of Ad7 disease, rang-
ing from mild upper respiratory illness to severe lower respira-
tory tract illness and death. Where civilian outbreaks of Ad7
illness were recognized, only one representative isolate was
included in the 166 sample for analysis. Approximately 10%
of Ad7 isolates from military recruits with respiratory illness
were sampled from all five training sites and were selected to
be evenly spaced over the designated time period. Reference
strains Gomen and S-1058 were obtained from the American
Type Culture Collection (ATCC, Rockville, MD). Reference
isolates of Ad7d2 were obtained from a postmortem rectal
swab from a 4-month-old baby in Israel in 1993, and Ad7h
was obtained during a regional outbreak of respiratory illness
in Chile in 1998. All Ad isolates were passaged at least once in
A549 cells before restriction analysis. Type-specificity of all
Ad7 field isolates was confirmed by neutralization or Ad7
type-specific polymerase chain reaction assay (PCR) (39).
DNA Restriction Analysis
Ad genomic DNA was extracted by a modification of the
method of Deryckere and Burgert (40). Briefly, isolates were
grown in 75-cm2 confluent flasks of A549 cells until the 4+
stage of cytopathic effect was attained. The contents of the
flask were centrifuged at low speed to remove cells, and the
Table 1. Human adenovirus 7 (Ad7) field isolates from the United 
States and Canada, 1966–2000
Location Isolation year(s) No. Ad7 isolates
Canada
     Eastern Ontario 1999, 2000 3
United States  
     Alabama 1985, 1986 2
     Arizona 1995, 1998 3
     Californiaa 1997 1
     California 1981- 4, 1987, 1990, 1992, 
1995, 1996
15
     Colorado 1987 1
     Florida 1986, 1996 2
     Georgia 1996 1
     Illinoisa 1996 - 98 28
     Illinois 1997 2
     Iowa 2000 1
     Kansas 1995, 1997 3
     Louisiana 1996 2
     Maine 1981 1
     Maryland 1991, 1993 - 95 16
     Massachusetts 1998, 1999 2
     Michigan 1986 1
     Mississippi 1986 1
     Missouria 1997 9
     Missouri 1966, 1998, 1999 8
     New York 1970, 1985, 1990, 1991, 1993, 
1995-97, 1999, 2000
31
     Ohio 1993-95, 1997, 1998 10
     South Carolinaa 1997, 1998 11
     South Carolina 1998 1
     South Dakota 1987 1
     Tennessee 1997 2
     Texasa 1998 1
     Texas 1999, 2000 2
     Virginia 1985 1
     Washington 1996 1
     Wisconsin 1996, 1998 3
North America (total) 1966-2000 166
aAd7 isolates obtained from military recruit training centers.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 271
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supernatant was transferred to an ultra-centrifuge tube and
centrifuged for 2 hours at 100,000 x g. The virus pellet was
resuspended in 400 µL of Tris buffer (pH 7.4) with 1% sodium
dodecyl sulfate and sequentially digested with DNAse free
RNAse A (0.1 mg/mL) and proteinase K (0.5 mg/mL). The
digest was extracted twice with equal volumes of phenol and
chloroform/isoamylalcohol (24:1) and once with chloroform/
isoamylalcohol alone. The purified DNA was then precipitated
with absolute ethanol and washed once with 75% ethanol, and
the pellet was resuspended in 100 µL of dH2O. Enzyme diges-
tions were carried out according to manufacturer's instructions
(Boehringer Mannheim Biochemicals, Indianapolis, IN). DNA
from all Ad7 isolates was digested with BamHI and SmaI, and
selected isolates were also digested with enzymes BcII, BglI,
BglII, BstEII, EcoRI, HpaI,  HindIII,SalI,  XbaI, and XhoI.
Enzyme digests were electrophoresed at 100 volts for 5 hours
on 0.8% agarose gels, and the DNA bands were visualized by
ethidium bromide staining. Restriction fragment size(s) was
interpolated from DNA molecular weight standards
included in each run. Restriction patterns were compared
with previously published profiles (24,37,41,42), and the
identification of genome types followed the denomination
system of Li et al. (24).
DNA Sequencing
The hypervariable region of the hexon protein gene corre-
sponding to nucleotides 403 to 1356 (Gomen), which have
been shown to encode the residues that define Ad serotype,
was PCR amplified from selected Ad7 isolates as described
(43) and sequenced by using the DyeDeoxy Terminator Cycle
Sequencing Kit and ABI 373A automated DNA sequencer
(Applied Biosystems, Foster City, CA). Nucleotide sequences
were determined for both PCR product strands. Sequence anal-
ysis was performed by using the Wisconsin Package ver. 10.0
(Genetics Computer Group, Madison, WI). Hexon gene
sequence data for the reference Ad7d2 strain from Israel were
submitted to GenBank (accession number AF321311).
Results
Ad7 Genome Types Identified
DNA restriction analysis of the 166 Ad7 field isolates
identified 108 (65%) as Ad7b, 46 (28%) as Ad7d2, 4 (2%) as
Ad7h, 3 (2%) as Ad7p, 3 (2%) as Ad7a, and 2 (1%) as Ad7a3.
Restriction profiles of representative Ad7b, Ad7d2, and Ad7h
isolates for selected endonucleases are shown in the Figure.
All U.S. (and eastern Ontario, Canada) Ad7d2 isolates and an
Ad7d2 reference strain from Israel (37) gave identical restric-
tion patterns for BamHI,  BcII,  BglI,  BglII, BstEII, EcoRI,
HpaI, HindIII, SalI, SmaI, XbaI, and XhoI. Identical restriction
profiles were also obtained with four U.S. Ad7h isolates and a
1998 isolate of Ad7h from Chile, which were similar to pro-
files described for Ad7h strains isolated in Argentina and
Chile (formerly designated Ad3f) (41,42,44). 
Ad7 Hexon Gene Sequencing
The hypervariable regions of the hexon gene (correspond-
ing to nucleotides 403 to 1356 of the reference strain Gomen)
of 24 temporally and geographically diverse Ad7 field isolates
(including 11 Ad7b, 10 Ad7d2, and 3 Ad7h and laboratory
strains S-1058, 55142 vaccine, and Gomen) were sequenced
and compared with published Ad7 hexon sequences available
from GenBank (Table 2). Nucleotide and deduced amino acid
alignments of these sequences comprised two major genetic
clusters as previously described (26,45): cluster 1, Ad7p
(Gomen) and Ad7p1; and cluster 2, Ad7a Ad7b, Ad7c, Ad7d,
Ad7d2, Ad7g, and Ad7h. Cluster 2 sequences were highly
conserved, with over 98% nucleotide identity, and were gener-
ally uncorrelated with genome type. However, a unique Gln
substitution for Leu (codon CTG > CAG) at amino acid posi-
tion 443 of loop 2 of the predicted hexon protein was identi-
fied in all 10 Ad7d2 isolates from the United States and Israel;
this substitution was also present in published hexon
sequences of Ad7d isolates from China (45) and Japan (38).
Temporal Distribution of Ad7 Genome Types
The yearly distribution of the 166 Ad7 genome types is
shown in Table 3. Ad7b was the only genome type identified
from 1970 through 1992 and was the predominant genome
type identified through 2000. Ad7d2 first appeared among
1993 isolates and accounted for approximately 28% of all Ad7
isolates obtained from 1993 to 2000. Four epidemiologically
unrelated isolates of Ad7h were identified in 1998 and 2000.
Figure. Restriction profiles of representative human adenovirus (Ad)
genome types Ad7b (1), Ad7d2 (2), and Ad7h (3) after digestion with
selected enzymes, BamHI, Sma I, BstEII, BglII, and BcII. DNA markers
II (M HindIII) and III (M HindIII/EcoRI).RESEARCH
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Table 2. Human adenovirus 7 (Ad7) field isolates and laboratory strains used for hexon gene sequence comparisons
ID Genome type Location Isolation year Accession no. Sequence sourcea
S-1058 7a USA 1955 af053085 Inada & Mukoyama, direct submission; CDC
55142 vaccine 7a3 USA 1963 af065067 Crawford-Miksza et al. (26); CDC
BC30 7b China 1958 u75951 Li & Wadell (45)
BC14 7b China 1965 u77390 Li & Wadell (45)
KCH4 7b England 1973 u77391 Li & Wadell (45)
v2026 7b USA, MI 1986   CDC
v2124 7b USA, SD 1987   CDC
2000017657 7b USA, MD 1991 CDC
99026790 7b USA, OH 1993 CDC
2000017667 7b USA, MD 1994   CDC
2000026630 7b USA, NY 1996 CDC
Kn T96-0620 7b USA, CA 1996 af065068 Crawford-Miksza et al. (26)
99018141 7b USA, MO 1997 CDC
2000016352 7b USA, IL 1997   CDC
2000016376 7b USA, SC 1997   CDC
2000016361 7b USA, MO 1997 CDC
2000016376 7b USA, SC 1997 CDC
37300 7c Sweden 1964 u75952 Li & Wadell, (45)
BC3655 7d China 1981 u77392 Li & Wadell, (45)
BC4492 7d China 1984 u75953 Li & Wadell, (45)
BC4609 7d China 1984 u77393 Li & Wadell (45)
BC8488 7d China 1984 u77394 Li & Wadell (45)
383b 7d Japan 1992 af053086 Hashido et al. (38)
Balb 7d Japan 1995 af053087 Hashido et al. (38)
2000017663 7d2 USA, MD 1993   CDC
2000026865 7d2 Israel 1993 af321311 CDC
2000017669 7d2 USA, MD 1994   CDC
2000026621 7d2 USA, NY 1995   CDC
99026817 7d2 USA, OH 1995   CDC
2000016333 7d2 USA, IL 1997   CDC
2000016364 7d2 USA, MO 1997 CDC
2000016375 7d2 USA, SC 1997   CDC
98034168 7d2 USA, IL 1998   CDC
2000017983 7d2 USA, WI 1998   CDC
BC25 7g China 1985 u75954 Li & Wadell (45)
87-922 7h Argentina 1987 u75956 Li & Wadell (45)
990179044 7h Chile 1998 CDC
99018196 7h USA, AZ 1998 CDC
2000016378 7h USA, TX 1998   CDC
Gomen 7p USA 1954 z48571 Li et al., direct submission; CDC
BC3423 7p1 China 1981 u75955 Li & Wadell (45)
aSequencing and restriction analysis performed at Centers for Disease Control and Prevention (CDC) or obtained from previously published sources. Published sequences of Ad7 lab-
oratory strains S-1058, Gomen, and 55142 vaccine confirmed at CDC.
bAd7 strains 383 and Bal were originally reported as Ad7d with a "different restriction pattern by BstEII" (38).Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 273
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Geographic Distribution of Ad7 Genome Types
Ad7b was identified among isolates from nearly all states
(and eastern Ontario) sampled. Ad7d2 was first identified in
isolates from Maryland and New York in 1993 and thereafter
primarily from midwestern and northeastern states, including
Wisconsin, Illinois, Kansas, Missouri, Louisiana, South Caro-
lina, and Ohio, as well as eastern Ontario. Ad7h was only
identified among isolates obtained from Texas and Arizona. 
Ad7 Civilian Outbreaks, 1996–2000
During this study, we became aware of five separate out-
breaks of Ad7 respiratory illness among civilians (Table 4).
Four were institutional outbreaks that involved primarily
infants and young children with underlying chronic disease
that occurred in the fall or summer months of 1996, 1998,
1999, and 2000. A fifth communitywide outbreak of Ad7 in
Tennessee, which occurred during March-July 1997, involved
previously healthy children (16).Genome type analysis at CDC
identified Ad7d2 in three of the four outbreaks where isolates
were available. We attributed one outbreak to a novel Sma I
restriction variant of Ad7b (Ad7bvar) that occurred in New
York in 1999 (Jennifer Calder, manuscript in preparation).
Ad7 Gnome Types at Military Recruit Training Centers
In anticipation of increased Ad activity following termina-
tion of routine vaccination of new military recruits in 1996, the
Naval Health Research Center (NHRC) in San Diego, CA, ini-
tiated surveillance for new cases of Ad-associated respiratory
illness (20) [http://www.nhrc.navy.mil/geis/sites/nhrc.htm].
Clinical specimens collected at five designated training centers
(San Diego, CA; San Antonio, TX; St. Robert, MO; Great
Lakes, IL; and Columbia, SC) from recruits who reported res-
piratory illness were submitted to NHRC for identification of
viral and bacterial pathogens. Of 50 Ad7 isolates, Ad7d2 was
the most common genome type identified (58%), followed by
Ad7b (34%), Ad7p (6%), and Ad7h (2%) (Table 5). Most
Ad7d2 infections were reported from the Naval Recruit Train-
ing Center in Great Lakes, IL, where an outbreak of Ad7 (and
Ad3) respiratory illness was documented during the fall of
1997 (21). Over 70% of the Ad7 isolates sampled from the
Great Lakes Center from September 1997 to February 1998
were identified as Ad7d2. One of four Ad7h isolates identified
in this study was obtained from a new recruit at Lackland Air
Force Base, in San Antonio.
Table 3. Yearly distribution of 166 human adenovirus 7 (Ad7) genome types, United States and Canada, 1966–2000
Genome type 1966-1969 1970-1992 1993 1994 1995 1996 1997a 1998a 1999 2000 Total
7 p 0 0 0 000 3 0 0 0 3
7 a 3 0 0 000 0 0 0 0 3
7 a 3 2 0 0 000 0 0 0 0 2
7b 0 31 6 4 14 8 26 4 6 8 107
7bvar 0 0 0 000 0 0 1 0 1
7d2 0 0 2 1 3 4 32 2 0 2 46
7 h 0 0 0 000 0 3 0 1 4
Total 5 31 8 5 17 12 61 9 7 11 166
aData include 50 Ad7 isolates collected in 1997 (47 isolates ) and 1998 (3 isolates ) from military recruit training centers (Table 4).












Houma, LAb June 1996 Pediatric chronic-care facility 13 7 4 2 7d2
Memphis, TNc Mar 1997 Community acquired 47 1 26 0 nd
Chicago, ILd Nov 1998 Pediatric chronic-care facility 31 8 11 11 7d2
       and tertiary hospital 37 0 6 6 "
New York City, NYe Oct 1999 Chronic-care facility formentally 
disabled persons 
33 7 15 15 7bvar
Des Moines, IAf Oct 2000 Pediatric chronic-care facility 20 4 9 9 7d2
aSuspected and confirmed cases of Ad7 respiratory disease.
bRobert Gohd, Children's Hospital, New Oreleans, LA (pers. comm.).
cMitchell et al. (16).
dGerber et al. (17).
eJennifer Calder, The Mailman School of Public Health, Columbia University, New York, NY (manuscript in preparation).
fMichael Buley, Iowa Dept of Public Health, Des Moines, IA (pers. comm.).RESEARCH
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Discussion
Our study represents the most comprehensive survey to
date of Ad7 genome types circulating in the United States and
provides a basis for future surveillance studies that can better
delineate the disease impact of these viruses. 
Before this study, the most comprehensive surveys of Ad7
genomic variants in the United States were conducted by
Wadell et al. (27) and Adrian et al. (28) with field isolates of
Ad7 collected from 1961 to 1985. These authors identified a
diverse group of cocirculating Ad7 genome types (Ad7p,
Ad7a, Ad7c, and others) that by the late 1960s to early 1970s
were replaced by Ad7b, a change that preceded similar shifts
to Ad7b seen in other parts of the world. Our data confirm this
observation and show a continued dominance of the Ad7b
genome type in the United States. Only one genome type from
the earlier period, Ad7p, was still identified among currently
circulating strains. We also documented the appearance of two
new Ad7 genome types: Ad7d2, which was first identified in
specimens collected in 1993 and subsequently detected over a
wide geographic area in the eastern half of the United States
and Canada; and Ad7h, which was first identified in speci-
mens collected in 1998 in the Southwest. 
Both epidemiologic and molecular evidence suggests that
Ad7d2 entered the United States as part of its recent spread
from evolutionarily related Ad7d strains formerly restricted to
China. Ad7d2 shows the highest degree of genetic relatedness
to Ad7d, differing by only one BstEII restriction site in pair-
wise comigrating restriction fragment analysis with 12 differ-
ent endonucleases (24,37); it possesses the unique amino acid
substitution in the hexon protein also present in Ad7d isolates
from China (45) and Japan (38). Ad7d was identified as early
as 1980 in Beijing (24) and 2 years later in Changchin (46),
and rapidly displaced Ad7b to become the major genome type
circulating in China through 1990. Ad7d was identified in
Japan during 1987 to 1992 (35) and in Korea in 1995 (18;
Hoan-Jong Lee, pers. comm.), and Ad7d2 was the predomi-
nant genome type isolated during the 1995-1998 Ad7 epi-
demic in Japan (15,36). Ad7d2 was subsequently identified in
Israel in 1992 (37) and in the United States in this study in
1993.
The emergence and apparent global spread of Ad7d2 are
reminiscent of observations for another genome type of sero-
type 7, Ad7b. Originally described by Wadell and Varsanyi
(25), Ad7b was associated with outbreaks of severe respiratory
illness in Europe in the 1970s (12). Although first isolated in
1956 from a Paris orphanage outbreak (12,47), subsequent ret-
rospective studies did not identify Ad7b in Europe again until
1969 (27).  Before then, the earliest documented occurrence of
Ad7b was in China in 1958 (24), where it was the predominant
genome type circulating through the early 1980s (24,46). With
the exception of Paris, the first appearance of Ad7b outside
China was on the U.S. West Coast in 1962 (27). By 1970,
Ad7b was the predominant genome type circulating through-
out the United States (28) and eventually throughout many
parts of the world.
The mechanism(s) underlying the apparent greater fitness
of some Ad7 genome types, as reflected by their capacity to
displace other circulating strains, remains speculative. Possi-
ble explanations include mutations or recombinations that
yield strains with increased pathogenicity and therefore greater
chance of causing recognized illness, or biological or antigenic
changes that enhance transmission or infection compared with
other Ad7 genome types. Although there is no conclusive evi-
dence of differences in pathogenicity between Ad7 genome
types, some types appear to be more frequently isolated from
healthy carriers (e.g., Ad7p and Ad7a), while others are more
often isolated from patients with more serious clinical out-
comes (e.g., Ad7b, Ad7c, Ad7d, and Ad7h) (27,34). Some
antigenic differences between Ad7 genome types have also
been demonstrated; recent studies identified minor differences
in neutralization titer between Ad7 prototype strain Gomen
(Ad7p) and the vaccine strain 55142 (Ad7a) with rabbit hyper-
immune antisera (26). In addition, a unique amino acid substi-
tution in the hexon protein that distinguishes Ad7d/Ad7d2














7b 7d2 7p 7h
Marine Corps Recruit Depot, San 
Diego, CA
129 128 10 (8) 1 April 1997 1
Lackland Air Force Base, San 
Antonio, TX
1 1 1 (100) 1 April 1998 1
Fort Leonard Wood, St. Robert, 
MO
266 260 29 (11) 9 Feb 1997 to Nov 
1997
45
Naval Recruit Training Center, 
Great Lakes, IL
632 592 396 (67) 28 Sept 1997 to May 
1998
82 0
Fort Jackson, Columbia, SC 786 738 66 (9) 11 June 1997 to April 
1998
542
Total 1,814 1,719 502 (29) 50 17 29 3 1
aIsolation and serotyping of Ads conducted at the Naval Health Research Center, San Diego, CA. Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 275
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strains from other genome types is predicted to impart substan-
tial changes in the hydrophilicity of the protein and possibly
associated antigenic changes (45).
Although Ad7 can be spread directly by the respiratory
route, efficiency of transmission is typically lower than for
some other respiratory viruses. Efficient spread usually
requires crowding, such as that in closed communities like
chronic-care facilities, military barracks, and day-care centers.
Widespread community outbreaks of Ad7 can occur but
appear to require low levels of herd immunity. For example, in
Japan, >95% of persons <40 years of age lacked specific anti-
bodies to Ad7 before the countrywide epidemic of Ad7 that
began in 1995 (48,49). The most comprehensive recent sero-
prevalence data on Ad7 in the United States were obtained in
1992 from 364 military basic trainees attending new recruit
training centers (50). Approximately 73% of screened trainees
lacked specific antibodies to Ad7. In another study to evaluate
the potential for use of Ad vectors in gene therapy for cystic
fibrosis, 73.9% of 46 serum specimens collected from 1993 to
1995 from children (median age 4.7 years) were seronegative
for Ad7 (51).
To achieve rapid spread, a novel genome type presumably
requires an immunologically naive population, greater biologi-
cal fitness than the indigenous circulating strains, and a means
of introduction to the susceptible community. Azar et al. (37)
noted that the appearance of Ad7d2 in Israel coincided with
the arrival of large numbers of immigrants from the former
Soviet Union and Ethiopia during the early 1990s. The global
spread of Ad7b in the 1960s and 1970s may have been aided
by the movement of unvaccinated U.S. and allied military per-
sonnel during the Vietnam War. In our study, the appearance of
Ad7h in the U.S. Southwest in 1998 may be explained by the
emigration of persons from Ad7h-endemic regions of South
America, where communitywide outbreaks of respiratory ill-
ness due to Ad7h occurred as recently as 1998 in Chile (Rod-
rigo Fasce, pers. comm.). However, a more comprehensive
survey of Ad7 isolates from Mexico and U.S. states on the Mex-
ican Border would be necessary to substantiate this observation. 
The five recognized civilian outbreaks of Ad7 respiratory
illness that occurred during 1996-2000, three of which we
attributed to genome type 7d2, might have been due to
increased reporting as a result of our interest in this study or
may represent a real increase in Ad7-associated disease, as
occurred in Europe during the early 1970s and in Japan and
Korea (12,15,18) beginning in 1995. One unsubstantiated pos-
sibility is that the discontinuation of vaccination of U.S. mili-
tary recruits for Ad4 and Ad7 in 1996 and the subsequent
increase in Ad-associated disease at military bases throughout
the United States (20-22) provided a new focus for Ad7 dis-
semination to civilian populations. A possible example of this
is the 1998 outbreak of Ad7d2 illness at a Chicago pediatric
chronic-care facility described earlier (17). This outbreak
occurred within a few miles of the Naval Training Center in
Great Lakes, which had had an outbreak of Ad7d2 the preced-
ing year (21). Most cases of Ad infection at military bases
since 1996 have been attributed to Ad4 (20,22), but no compa-
rable outbreaks of Ad4 disease among civilians have been
reported. Unlike Ad7, which poses a risk to both civilian and
military populations, Ad4 has only infrequently been associ-
ated with outbreaks of respiratory illness in civilian popula-
tions (2).
Although we identified individual cases of severe lower
respiratory tract illness and deaths attributed to Ad7d2 and
Ad7h in this study, the possibility that these two genome types
may be associated with more severe disease is not yet clear.
More extensive clinical and epidemiologic study is required to
adequately address this question. The limited data from
infected military recruits suggest no differences in clinical ill-
ness between those infected with Ad7d2 and Ad7b (data not
shown). Reports of Ad7d2 infections in Israel (37) and Ad7d
infections in China (46) also noted no clear differences in
severity of disease. Cases of severe pneumonia and neurologic
disease were reported from a recent regional epidemic of
Ad7d2 in Japan (15), but there was no evidence that these
severe cases were more common than those reported for out-
breaks involving other Ad7 genome types. Ad7h, a genetically
unique recombinant between Ad7 and Ad3 (42), has been
linked to increased illness and death in infants in Chile and
Argentina, where it is second only to Human respiratory syn-
cytial virus as a cause of severe viral pneumonia in infants and
young children (34,52). However, in this study, too few cases
of Ad7h infection were identified to assess differences in dis-
ease severity.
In conclusion, our study documents the recent appearance
in the United States of two new Ad7 genome types, Ad7d2 and
Ad7h, and provides additional evidence of the global spread of
these formerly geographically restricted viruses. The possibil-
ity that these genome types may be associated with more
severe disease makes it prudent to monitor their spread and
associated disease.
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